Literature DB >> 23671115

Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction.

Christopher W Waters1, Grigor Varuzhanyan, Robert J Talmadge, Andrew A Voss.   

Abstract

Huntington disease is a progressive and fatal genetic disorder with debilitating motor and cognitive defects. Chorea, rigidity, dystonia, and muscle weakness are characteristic motor defects of the disease that are commonly attributed to central neurodegeneration. However, no previous study has examined the membrane properties that control contraction in Huntington disease muscle. We show primary defects in ex vivo adult skeletal muscle from the R6/2 transgenic mouse model of Huntington disease. Action potentials in diseased fibers are more easily triggered and prolonged than in fibers from WT littermates. Furthermore, some action potentials in the diseased fibers self-trigger. These defects occur because of decreases in the resting chloride and potassium conductances. Consistent with this, the expression of the muscle chloride channel, ClC-1, in Huntington disease muscle was compromised by improper splicing and a corresponding reduction in total Clcn1 (gene for ClC-1) mRNA. Additionally, the total Kcnj2 (gene for the Kir2.1 potassium channel) mRNA was reduced in disease muscle. The resulting muscle hyperexcitability causes involuntary and prolonged contractions that may contribute to the chorea, rigidity, and dystonia that characterize Huntington disease.

Entities:  

Keywords:  channelopathy; electrophysiology; myopathy; myotonia; trinucleotide repeat

Mesh:

Substances:

Year:  2013        PMID: 23671115      PMCID: PMC3670332          DOI: 10.1073/pnas.1220068110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  The influence of potassium and chloride ions on the membrane potential of single muscle fibres.

Authors:  A L HODGKIN; P HOROWICZ
Journal:  J Physiol       Date:  1959-10       Impact factor: 5.182

2.  Gene expression in Huntington's disease skeletal muscle: a potential biomarker.

Authors:  Andrew D Strand; Aaron K Aragaki; Dennis Shaw; Thomas Bird; Janice Holton; Christopher Turner; Stephen J Tapscott; Sarah J Tabrizi; Anthony H Schapira; Charles Kooperberg; James M Olson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

3.  Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing.

Authors:  M A Hickey; K Gallant; G G Gross; M S Levine; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2005-10       Impact factor: 5.996

4.  Myosin heavy chain isoform mRNA and protein levels after long-term paralysis.

Authors:  Robert J Talmadge; Nicole D Garcia; Roland R Roy; V Reggie Edgerton
Journal:  Biochem Biophys Res Commun       Date:  2004-12-03       Impact factor: 3.575

5.  Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1.

Authors:  John D Lueck; Codrin Lungu; Ami Mankodi; Robert J Osborne; Stephen L Welle; Robert T Dirksen; Charles A Thornton
Journal:  Am J Physiol Cell Physiol       Date:  2006-11-29       Impact factor: 4.249

6.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.

Authors:  Carsten Saft; Jochen Zange; Jürgen Andrich; Klaus Müller; Katrin Lindenberg; Bernhard Landwehrmeyer; Matthias Vorgerd; Peter H Kraus; Horst Przuntek; Ludger Schöls
Journal:  Mov Disord       Date:  2005-06       Impact factor: 10.338

7.  Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current.

Authors:  Jim Berg; Hong Jiang; Charles A Thornton; Stephen C Cannon
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

8.  Striatal potassium channel dysfunction in Huntington's disease transgenic mice.

Authors:  Marjorie A Ariano; Carlos Cepeda; Christopher R Calvert; Jorge Flores-Hernández; Elizabeth Hernández-Echeagaray; Gloria J Klapstein; Scott H Chandler; Neil Aronin; Marian DiFiglia; Michael S Levine
Journal:  J Neurophysiol       Date:  2004-12-29       Impact factor: 2.714

9.  Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.

Authors:  Richard R Ribchester; Derek Thomson; Nigel I Wood; Tim Hinks; Thomas H Gillingwater; Thomas M Wishart; Felipe A Court; A Jennifer Morton
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

10.  Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs.

Authors:  Yuan Yuan; Sarah A Compton; Krzysztof Sobczak; Myrna G Stenberg; Charles A Thornton; Jack D Griffith; Maurice S Swanson
Journal:  Nucleic Acids Res       Date:  2007-08-15       Impact factor: 16.971

View more
  32 in total

1.  Treatment of myotonia congenita with retigabine in mice.

Authors:  Chris Dupont; Kirsten S Denman; Ahmed A Hawash; Andrew A Voss; Mark M Rich
Journal:  Exp Neurol       Date:  2019-02-07       Impact factor: 5.330

2.  Mapping ligand binding pockets in chloride ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid.

Authors:  C Altamura; G F Mangiatordi; O Nicolotti; D Sahbani; A Farinato; F Leonetti; M R Carratù; D Conte; J-F Desaphy; P Imbrici
Journal:  Br J Pharmacol       Date:  2018-04-06       Impact factor: 8.739

3.  Levator Auris Longus Preparation for Examination of Mammalian Neuromuscular Transmission Under Voltage Clamp Conditions.

Authors:  Steven R A Burke; Eric J Reed; Shannon H Romer; Andrew A Voss
Journal:  J Vis Exp       Date:  2018-05-05       Impact factor: 1.355

4.  Mechanisms of altered skeletal muscle action potentials in the R6/2 mouse model of Huntington's disease.

Authors:  Daniel R Miranda; Eric Reed; Abdulrahman Jama; Michael Bottomley; Hongmei Ren; Mark M Rich; Andrew A Voss
Journal:  Am J Physiol Cell Physiol       Date:  2020-05-20       Impact factor: 4.249

Review 5.  Discovery of CLC transport proteins: cloning, structure, function and pathophysiology.

Authors:  Thomas J Jentsch
Journal:  J Physiol       Date:  2015-08-24       Impact factor: 5.182

6.  Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.

Authors:  Ahmad Khedraki; Eric J Reed; Shannon H Romer; Qingbo Wang; William Romine; Mark M Rich; Robert J Talmadge; Andrew A Voss
Journal:  J Neurosci       Date:  2017-07-19       Impact factor: 6.167

Review 7.  Potassium channel dysfunction in neurons and astrocytes in Huntington's disease.

Authors:  Xiao Zhang; Jie-Qing Wan; Xiao-Ping Tong
Journal:  CNS Neurosci Ther       Date:  2018-01-27       Impact factor: 5.243

8.  Huntington's Disease-Induced Cardiac Disorders Affect Multiple Cellular Pathways.

Authors:  Girish C Melkani
Journal:  React Oxyg Species (Apex)       Date:  2016-09

9.  Clenbuterol-sensitive delayed outward potassium currents in a cell model of spinal and bulbar muscular atrophy.

Authors:  Vladimir A Martínez-Rojas; Daniele Arosio; Maria Pennuto; Carlo Musio
Journal:  Pflugers Arch       Date:  2021-05-22       Impact factor: 3.657

10.  Huntington's disease skeletal muscle has altered T-tubules.

Authors:  Muhammad S Khan; Robin M Shaw
Journal:  J Gen Physiol       Date:  2021-05-12       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.